The economic benefit of photodynamic diagnosis in non-muscle invasive bladder cancer

Photodiagnosis and Photodynamic Therapy

Volumn 5, Issue 2, 2008, Pages 153-158

  Dindyal, Sanjay ^a   Nitkunan, Tharani ^a   Bunce, Colin J ^a  

^a ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Bladder; Cancer; Economic; Photodynamic; Recurrence

Indexed keywords

AMINOLEVULINIC ACID; PORPHYRIN; PROTOPORPHYRIN;

BLADDER CANCER; BLADDER MUSCLE; BLADDER PERFORATION; BLUE LIGHT; CANCER DIAGNOSIS; CANCER RECURRENCE; CARCINOMA IN SITU; CLINICAL TRIAL; COST OF ILLNESS; CYSTOSCOPY; DIAGNOSTIC PROCEDURE; DRUG MECHANISM; ECONOMIC ASPECT; ENDOSCOPIC SURGERY; FOLLOW UP; HUMAN; PHOTODYNAMICS; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; TRANSURETHRAL RESECTION; WHITE LIGHT;

AMINOLEVULINIC ACID; CARCINOMA, TRANSITIONAL CELL; FLUORESCENCE; HUMANS; NEOPLASM INVASIVENESS; PHOTOCHEMOTHERAPY; URINARY BLADDER NEOPLASMS;

EID: 46749120915     PISSN: 15721000     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pdpdt.2008.05.001     Document Type: Review

References (31)

1. Lee R., and Droller M.J. The natural history of bladder cancer. Implications for therapy. Urol Clin North Am 27 1 (2000) 1-13 vii
2. Schellhammer P.F. Immediate adjuvant intravesical chemotherapy after transurethral resection of bladder tumour. Curr Opin Urol 8 5 (1998) 407-409
3. Holzbeierlein J.M., and Smith Jr. J.A. Surgical management of noninvasive bladder cancer (stages Ta/T1/CIS). Urol Clin North Am 27 1 (2000) 15-24 vii-viii
4. Vogeli T.A., Grimm M.O., Simon X., and Ackermann R. Prospective study of effectiveness. Reoperation (re-TUR) in superficial bladder carcinoma. Urologe A 41 5 (2002) 470-474
5. Klan R., Loy V., and Huland H. Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder. J Urol 146 2 (1991) 316-318
6. Soloway M.S., Murphy W., Rao M.K., and Cox C. Serial multiple-site biopsies in patients with bladder cancer. J Urol 120 1 (1978) 57-59
7. Althausen A.F., Prout Jr. G.R., and Daly J.J. Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol 116 5 (1976) 575-580
8. Kappas A, Sassa S, Galbraith R, Nordmann Y. The porphyrias. In: Scriver C, Beaudet W, Sly D, Valle D, editors. New York: McGraw-Hill; 1989. p. 1305-66.
9. Kennedy J.C., and Pottier R.H. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B 14 4 (1992) 275-292
10. Sima A.A., Kennedy J.C., Blakeslee D., and Robertson D.M. Experimental porphyric neuropathy: a preliminary report. Can J Neurol Sci 8 2 (1981) 105-113
11. Pottier R.H., Chow Y.F., LaPlante J.P., Truscott T.G., Kennedy J.C., and Beiner L.A. Non-invasive technique for obtaining fluorescence excitation and emission spectra in vivo. J Photochem Photobiol B 44 (1986) 679-687
12. Kriegmair M., Baumgartner R., Knuechel R., et al. Fluorescence photodetection of neoplastic urothelial lesions following intravesical instillation of 5-aminolevulinic acid. Urology 44 6 (1994) 836-841
13. Steinbach P., Kriegmair M., Baumgartner R., Hofstadter F., and Knuchel R. Intravesical instillation of 5-aminolevulinic acid: the fluorescent metabolite is limited to urothelial cells. Urology 44 5 (1994) 676-681
14. Zaak D., Kriegmair M., Stepp H., et al. Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: results of 1012 fluorescence endoscopies. Urology 57 4 (2001) 690-694
15. Kriegmair M., Baumgartner R., Knuchel R., Stepp H., Hofstadter F., and Hofstetter A. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. J Urol 155 1 (1996) 105-109
16. Jichlinski P., Forrer M., Mizeret J., et al. Clinical evaluation of a method for detecting superficial surgical transitional cell carcinoma of the bladder by light-induced fluorescence of protoporphyrin IX following the topical application of 5-aminolevulinic acid: preliminary results. Lasers Surg Med 20 4 (1997) 402-408
17. Filbeck T., Roessler W., Knuechel R., Straub M., Kiel H.J., and Wieland W.F. Clinical results of the transurethreal resection and evaluation of superficial bladder carcinomas by means of fluorescence diagnosis after intravesical instillation of 5-aminolevulinic acid. J Endourol 13 2 (1999) 117-121
18. Koenig F., McGovern F.J., Larne R., Enquist H., Schomacker K.T., and Deutsch T.F. Diagnosis of bladder carcinoma using protoporphyrin IX fluorescence induced by 5-aminolaevulinic acid. BJU Int 83 1 (1999) 129-135
19. Riedl C.R., Plas E., and Pfluger H. Fluorescence detection of bladder tumors with 5-aminolevulinic acid. J Endourol 13 (1999) 755-759
20. De Dominicis C., Liberti M., Perugia G., et al. Role of 5-aminolevulinic acid in the diagnosis and treatment of superficial bladder cancer: improvement in diagnostic sensitivity. Urology 57 6 (2001) 1059-1062
21. Zaak D., and Hofstetter A. The current diagnosis of superficial bladder cancer must be reconsidered. Urol Int 69 2 (2002) 85-90
22. Kriegmair M., Zaak D., Rothenberger K.H., et al. Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. J Urol 168 2 (2002) 475-478
23. Riedl C.R., Daniltchenko D., Koenig F., Simak R., Loening S.A., and Pflueger H. Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer. J Urol 165 4 (2001) 1121-1123
24. Filbeck T., Pichlmeier U., Knuechel R., Wieland W.F., and Roessler W. Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors. J Urol 168 1 (2002) 67-71
25. Denzinger S., Burger M., Walter B., et al. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. Urology 69 4 (2007) 675-679
26. Botteman M.F., Pashos C.L., Redaelli A., Laskin B., and Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 21 18 (2003) 1315-1330
27. Riley G.F., Potosky A.L., Lubitz J.D., and Kessler L.G. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 33 8 (1995) 828-841
28. Sangar V.K., Ragavan N., Matanhelia S.S., Watson M.W., and Blades R.A. The economic consequences of prostate and bladder cancer in the UK. BJU Int 95 1 (2005) 59-63
29. Burger M., Zaak D., Stief C.G., et al. Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis. Eur Urol 52 1 (2007) 142-147
30. Hartmann A., Moser K., Kriegmair M., Hofstetter A., Hofstaedter F., and Knuechel R. Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma. Am J Pathol 154 3 (1999) 721-727
31. Stenzl A., Hoetl L., and Bartsch G. Fluorescence-assisted transurethral resection of bladder tumors: is it cost-effective?. Eur Urol 39 s5 (2001) 1-216